TrialScope is part of Informa Pharma Intelligence, a division of Informa Business Intelligence, Inc. (IBI). IBI is a wholly-owned subsidiary of Informa PLC.

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2019 Global Disclosure & Transparency Survey Now Open


May 3, 2019

JERSEY CITY, NJ – May 3, 2019 – TrialScope’s Global Clinical Trial Disclosure & Transparency Benchmark Survey 2019 is now open to clinical trial transparency professionals.

The 2019 survey is the third biennial assessment, establishing a disclosure benchmark across the last six years, thereby allowing disclosure professionals to gain insight into other organizations’ challenges and priorities, as well as benchmark their own capabilities against those of their peers. Topics covered include disclosure processes, policies, systems and more.

“In our last two surveys, we saw an increase in sponsor’s commitments to disclosure and transparency,” said Thomas Wicks, Chief Strategy Officer for TrialScope. “Given the increased scrutiny from regulatory bodies, patient advocacy groups and watchdog organizations, this increased focus should come as no surprise. I expect to see an even greater emphasis on clinical trial transparency in this year’s results.”

In an effort to encourage participation and promote global health, TrialScope is partnering with Greater Gift to donate vaccines to needy children. For each of the first 100 qualified survey participants, TrialScope will donate one vaccine.               

The deadline for survey responses is May 31. Participants will receive an advance copy of survey results. Access the online survey here.

About TrialScope 

TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 13 of the top 15 industry clinical trial sponsors worldwide. TrialScope provides proven solutions that optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit